News articles about Achillion Pharmaceuticals (NASDAQ:ACHN) have been trending somewhat positive on Tuesday, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.7324406301614 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Achillion Pharmaceuticals, Inc. (ACHN) stock moves 44.86% high in recent 30 days – The Stocks News (press release) (thestocksnews.com)
- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) – Is the Stock Overvalued? – Nasdaq Journal (nasdaqjournal.com)
- Achillion Pharmaceuticals, Inc. (ACHN) – Unusual Volume Activity on Watch List – Wall Street Morning (wallstreetmorning.com)
- Achillion Pharmaceuticals, Inc. (ACHN) Short Interest Update (americanbankingnews.com)
- Achillion to Present at the Barclays Global Healthcare Conference – Nasdaq (nasdaq.com)
Shares of Achillion Pharmaceuticals (ACHN) traded down $0.10 on Tuesday, reaching $4.11. The company’s stock had a trading volume of 1,232,647 shares, compared to its average volume of 2,207,080. Achillion Pharmaceuticals has a one year low of $2.58 and a one year high of $5.66. The firm has a market capitalization of $583.29, a price-to-earnings ratio of -6.63 and a beta of 1.04.
Several research analysts recently weighed in on ACHN shares. Leerink Swann reiterated a “buy” rating and set a $5.00 price target on shares of Achillion Pharmaceuticals in a research report on Monday, December 11th. Zacks Investment Research raised Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, February 27th. BidaskClub raised Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, December 21st. Finally, B. Riley initiated coverage on Achillion Pharmaceuticals in a report on Thursday, February 8th. They issued a “neutral” rating and a $3.50 price objective on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $4.89.
TRADEMARK VIOLATION WARNING: This piece was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3259483/achillion-pharmaceuticals-achn-receives-daily-coverage-optimism-rating-of-0-12.html.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.